NCODA shared a post on LinkedIn:
“The message from ASCO 2025 is clear: oncology is evolving fast.
In this special bonus episode, NCODA’s Senior Manager of Clinical Initiatives, Kelly M. Brunk, PharmD, MBA(c), BCOP, breaks down key updates – from new data on bispecifics and ADCs to the earlier use of immunotherapy. Kelly explains why practices need to start preparing now. Plus, learn how NCODA’s Immunotherapy Hub can support your team in adapting to these changes.”
Proceed to the video attached to the post.
More posts featuring NCODA.